Precision Business Insights
Portfolio

 

Research Reports

Transdermal Drug Delivery Systems Market: Global Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2013 to 2017 and Forecast 2018 to 2024

Global Transdermal Drug Delivery Systems Market

 

By Application (Cardiovascular, Contraception, Pain Management / Neurological Disorders, Smoking Cessation, Others), By Technology (Electric Current, Electroporation, Radio Frequency, Thermal, Ultrasound, Others) and Geography -Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2013-2017 and Forecast 2018-2024

 

Global melanoma treatment market was valued at US $ XX Mn and expected to grow at XX% Compound Annual Growth Rate (CAGR) over 2018 to 2024.

 

Market Outline: Transdermal Drug Delivery Systems Market

Transdermal drug delivery systems are the self-contained, discrete dosage applied in the form of patches to the intact skin and delivers medication through the controlled rate. The main aim of transdermal patches is to deliver the medication into the systemic circulation at controlled rates to minimize the intra and interpatient variation.

 

Market Dynamics: Transdermal Drug Delivery Systems Market

Global transdermal drug delivery systems market is primarily driven by the advantages of transdermal delivery system such as high bioavailability, less painful drug delivery system compared to conventional drug delivery systems. In addition, transdermal drug delivery systems are non-invasive and have very fewer side effects. This is likely to positively impact the growth of the market. Furthermore, advancements in the transdermal drug delivery systems and recent product launch expected to bolster the market growth over the forecast period. However, the adaptation rates and compatibility of the many large sized drugs are expected to hamper the market growth during the forecast period.

 

Market Scope: Transdermal Drug Delivery Systems Market

Melanoma treatment market is segmented based on application, technology and geography

Based on application, global transdermal drug delivery systems market is segmented into

  • Cardiovascular
  • Contraception
  • Pain Management / Neurological Disorders
  • Smoking Cessation
  • Others

Based on technology, global transdermal drug delivery systems market is segmented into

  • Electric Current
  • Electroporation
  • Radio Frequency
  • Thermal
  • Ultrasound
  • Others

Based on region, global transdermal drug delivery systems market is segmented into

  • North America
  • Latin America
  • Asia Pacific
  • Europe
  • Middle East and Africa

 

Market Summary: Transdermal Drug Delivery Systems Market

Global transdermal drug delivery systems market expected to grow at significant rates owing to the factors such as increase R&D to advance the transdermal drug delivery systems. Companies operating in the market are adopting acquisitions and mergers as these key strategies to leverage market share. For instance, in December 2016, Luye Pharma Group has acquired TDDS business from Acino international AG to expand its R&D and product portfolio. Furthermore, market also experiencing new product launches and advent of technologically advanced products. For instance, the 3M company has launched 3MScotchpakWhite release liners and white backing films aimed to improve the use of topical products.

 

Regional Analysis:  Transdermal Drug Delivery Systems Market

Geographically, global melanoma treatment market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. North America transdermal drug delivery systems market is expected to grow at significant rates owing to the factors such as presence of key market players and increase in the number of surgical procedures and prevalence of cardiovascular disorders. According to American Heart Association, incidence of heart disease in U.S. is about 58000 in 2014. Europe transdermal drug delivery system market expected to grow at notable rates owing to prevalence of the cardiovascular disorders and growing R&D investments in development of transdermal drug delivery systems. Asia Pacific transdermal drug delivery systems market is expected to have lucrative growth opportunity owing to development of healthcare infrastructure, growing R&D investments and growing awareness related to the advantages of transdermal drug delivery systems.

 

Competition Assessment: Transdermal Drug Delivery Systems Market

Some of the players in the global transdermal drug delivery systems market include:

  • Novartis AG (Switzerland)
  • Boehringer Ingelheim GmbH (Germany)
  • Generex Biotechnology Corp. (Canada)
  • Echo Therapeutics, Inc. (U.S.)
  • Crescita Therapeutics Inc (Canada)
  • MedPharm (U.K.)
  • Pantec Biosolutions AG (Liechtenstein)
  • Transdermal Corp. (U.S.)
  • Noven Pharmaceuticals, Inc. (U.S.)
  • Actelion Pharmaceuticals Ltd (Switzerland)
  • Johnson & Johnson Limited (U.S.)
  • 3M Pharmaceuticals Inc. (U.S.)
  • Mylan Pharmaceuticals Inc. (U.S.)
  • GlaxoSmithKline plc (U.K.)

 

Key Features of the Report:

  • The report provides granular level information about the market size, regional market share, historic market (2013-2017) and forecast (2018-2024)
  • The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments and startup’s details that are actively working in the market
  • The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario
  • The report analyses the impact of the socio-political environment through PESTLE Analysis and competition through Porter’s Five Force Analysis in addition to recent technology advancements and innovations in the market
  • Novartis AG (Switzerland)
  • Boehringer Ingelheim GmbH (Germany)
  • Generex Biotechnology Corp. (Canada)
  • Echo Therapeutics, Inc. (U.S.)
  • Crescita Therapeutics Inc (Canada)
  • MedPharm (U.K.)
  • Pantec Biosolutions AG (Liechtenstein)
  • Transdermal Corp. (U.S.)
  • Noven Pharmaceuticals, Inc. (U.S.)
  • Actelion Pharmaceuticals Ltd (Switzerland)
  • Johnson & Johnson Limited (U.S.)
  • 3M Pharmaceuticals Inc. (U.S.)
  • Mylan Pharmaceuticals Inc. (U.S.)
  • GlaxoSmithKline plc (U.K.)

A complementary 2hrs free facility through which report buyers can interact with our pool of experienced analysts for any report related queries, clarifications or additional data requirements

$ 3,000.00$ 8,900.00
Clear selection

Select License Type

Databank $ 3,000.00
spinner
Single User $ 4,400.00
spinner
Multiple User $ 6,600.00
spinner
Corporate User $ 8,900.00
spinner
buy now spinner
FacebookTwitterLinkedinEmail

Our Clients

Testimonials